Drug Pipeline Report 2H 2026

IPD Analytics has released a new report: "Drug Pipeline Report for 2H 2026."

With 43 high-impact drugs nearing potential FDA approval over the next 12 months, the 2H 2026 pipeline carries significant implications for payers, providers, and manufacturers alike. 27% of pipeline drugs target neurology indications, including therapies for myasthenia gravis, muscular dystrophy, narcolepsy, and Parkinson's disease. 42% are designated for rare diseases, 81% are classified as specialty drugs, and 30% are associated with an emerging biomarker. Nearly 50% of therapies are projected to carry an annual or per-treatment cost exceeding $300,000, with three potentially reaching $3 million or more. From a benefit design standpoint, 65% are expected to fall under the pharmacy benefit and 26% under the medical benefit.

For payers, proactive planning is essential. This report is designed to support P&T committee reviews, coverage policy updates, and management strategy adjustments before these therapies hit the market.

Content on this site is proprietary to IPD Analytics. This sample is not for distribution. By receiving it, you agree to refrain from any unauthorized use, including uploading or inputting it into AI tools or large language models (LLMs) for training or any other purpose. This is strictly prohibited.